Sanofi’s research focus may shift under new CEO Belén Garijo, amid gene therapy advances and telehealth debates

Sanofi is entering a period of strategic reassessment as Belén Garijo assumes the chief executive role. Observers are watching to see whether the company will adjust its recent emphasis on immunology after mixed results.

A gene‑therapy approach targeting certain forms of deafness is beginning to show real‑world benefits, highlighting the potential of advanced genetic treatments in the biotech pipeline.

At the same time, ultra‑low‑cost telehealth services are sparking debate about whether easier prescription access might compromise patient care quality.

In a related political note, RFK Jr. expressed a different perspective on vaccines during a recent congressional appearance, adding another layer to the ongoing public health conversation.